METHODS AND MEANS FOR STRATIFICATION OF AN INDIVIDUAL SUFFERING FROM, OR SUSPECTED TO SUFFER FROM, A PROGRESSIVE NEURODEGENERATIVE DISEASE
The invention relates to method for typing a sample of an individual suffering from, or is suspected to suffer from, a progressive neurodegenerative disease. The invention further relates to methods for assigning a treatment of the individual, based on said typing.
1 . A method for typing a sample of an individual suffering from a progressive neurodegenerative disease such as Alzheimer's disease (AD), comprising the steps of:
providing a sample from the individual, whereby the sample comprises gene expression products of said individual;
determining a level of expression for at least three gene expression products listed in Table 2;
comparing said determined levels of expression of each of the at least three gene expression products to a reference level of expression of each of the three gene expression products in a reference sample; and
typing said sample on the basis of the comparison of the determined levels of expression level and the level of expression in a reference sample.
2 . The method according to claim 1 , wherein the sample from the individual is or comprises a bodily fluid.
3 . The method according to claim 1 , wherein said determining step comprises determining the level of expression level for at least 6 gene expression products.
4 . The method according to any one of the previous claims, wherein the gene expression products are proteins.
5 . The method according to claim 1 , wherein the gene expression products are proteins indicated as CHGA, MASP1, and PLG.
6 . The method according to claim 1 , wherein a level of expression for at least three gene expression products is determined with the aid of an antibody or a functional part or equivalent thereof.
7 . The method according to claim 6 , wherein the antibody or a functional part or equivalent thereof is present on beads or on monolithic material.
8 . The method according to claim 1 , wherein a level of expression for at least three gene expression products is determined by flow cytometric immunoassay (FCIA).
9 . The method according to claim 1 , wherein determination of a level of expression for the at least three gene expression products further comprises mass spectrometry.
10 . The method according to claim 1 , wherein said typing results in the classification of the individual into a hyperplastic, a neuroinflammation, or a blood brain barrier (BBB) dysfunction subgroup.
11 . The method according to claim 1 , wherein said typing results in the classification of the individual into a hyperplastic, a neuroinflammation, a blood brain barrier (BBB) dysfunction, or a fourth subgroup.
12 . A method for assigning a β-secretase (beta-site APP cleaving enzyme 1, BACE1) inhibitor to an individual, comprising the steps of:
typing a sample of the individual according to a method of claim 1 , and
assigning a β-secretase inhibitor to an individual that is classified in the hyperplastic subgroup.
13 . A method for assigning an immune-modulating agent to an individual, comprising the steps of:
typing a sample of the individual according to a method of claim 1 , and
assigning an immune-modulating to an individual that is classified in the neuroinflammation subgroup.
14 . A method for assigning a anti-tau and/or anti-beta amyloid antibody to an individual, comprising the steps of:
typing a sample of the individual according to a method of claim 1 , and
assigning an anti-tau and/or anti-beta amyloid antibody to an individual that is classified in a BBB dysfunction subgroup.
15 . A method for assigning a block copolymer to an individual, comprising the steps of:
typing a sample of the individual according to a method of claim 1 , and
assigning a block copolymer, to an individual that is classified in a BBB dysfunction subgroup.
16 . The method according to claim 1 , wherein the neurodegenerative disease is Alzheimer's disease.
17 . The method according to claim 2 , wherein the bodily fluid is cerebrospinal fluid (CSF).
18 . The method according to claim 3 , wherein the determining step comprises determining the level of expression for at least 9 gene products in Table 2.
19 . The method according to claim 3 , wherein the determining step comprises determining the level of expression for at least 12 gene products in Table 2.
20 . The method according to claim 3 , wherein the determining step comprises determining the level of expression for all 369 gene expression products listed in Table 2.
21 . The method according to claim 15 , wherein the block copolymer is poly(ethylene oxide) and poly(propylene oxide) and/or a corticosteroid.